Last reviewed · How we verify

NCT03768765

Duration of Medication Therapy and Outcomes After Holmium Laser Prostate Surgery for Patients With Benign Prostatic Hyperplasia (BPH)

Terminated Last updated 2 October 2024
What this trial tests

trial testing Holmium Laser Prostate Surgery in Benign Prostatic Hyperplasia in 144 participants. Terminated before completion.

Timeline
15 November 2018
Primary endpoint
19 June 2024
27 August 2024

Quick facts

Lead sponsorUniversity of Kansas Medical Center
StatusTerminated
Study typeOBSERVATIONAL
Enrollment144
Start date15 November 2018
Primary completion19 June 2024
Estimated completion27 August 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Kansas Medical Center

Who can join

18 and older, any sex, with Benign Prostatic Hyperplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine if the prior prolonged use of medication, as a treatment for benign prostatic hyperplasia, reduces the efficacy of Holmium laser enucleation of the prostate (HoLEP) for patients with benign prostatic hyperplasia (BPH).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Benign Prostatic Hyperplasia

Currently open trials in the same condition.

Other University of Kansas Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03768765.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing